 |
 |
 |
Cytopia has discovered a new class of orally bioavailable drugs that target and disrupt tumor vasculature. Compounds of this chemical series are highly potent anticancer agents which are not susceptible to multi-drug resistance. |
 |
Read more |
|
|
 |
 |
|
Cytopia, through its access to crystal structures of members of the JAK family of kinases and chemistry capabilities, has been successful in developing a portfolio of small molecule inhibitors of JAK3 that are both potent and specific. |
|
Read more |
|
|
 |
 |
|
Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease (MPD), cancer and pulmonary hypertension (PAH). The lead compound, CYT387 is being developed for the treatment of various MPD’s |
|
Read more |
|
|
|
|
